
Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer
Presented by: Bayer
Sponsored by: Dendreon and Janssen Oncology
In-Kind Sponsor: Los Padres
- Dr. Edwin Morales – Urology Specialist, San Antonio
- Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
- Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
- Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
View the full video by clicking on the image below; or scroll down to access links to short video segments about specific content presented at the event.
Click any link listed below to go straight to that segment of the video:
- 0:01 – Introduction – Terri Likowski, Us TOO Program Director – Support Group Services
- 0:50 – Johnny Staha – Support Group Leader – San Antonio, TX
- 1:07 – Chuck Strand – CEO, Us TOO International
- 3:04 – Intro to Dr. Juan A. Reyna
- 4:44 – Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
- 10:00 – Intro to Dr. Edwin Morales
- 10:56 – Dr. Edwin Morales – Urology Specialist, San Antonio
- 11:01 – Prostate Cancer Overview, Definitions, Terms
- 11:52 – Biochemical Recurrence
- 14:29 – (Non) Metastatic Castrate Resistant Prostate Cancer
- 17:52 – The Androgen Receptor Axis
- 20:47 – Androgen Deprivation Therapy
- 21:17 – After ADT
- 23:00 – Options for Rising PSA After CAB/AAW
- 23:44 – Asymptomatic Non – Metastatic Castrate Resistant Prostate Cancer
- 26:36 – Options for Asymptomatic Non – Metastatic Castrate Resistant Prostate Cancer
- 32:16 – The "New" Natural History of Prostate Cancer
- 33:45 – Intro to Dr. Vijay Gunuganti
- 34:26 – Dr. Vijay Gunuganti – Oncologist at Texas Oncology
- 35:03 – Lifetime Probability of Developing Cancer
- 36:07 – Multidisciplinary Team Approach to PCa Management
- 37:02 – Treatment for CRPC
- 37:24 – Early Metastatic Prostate Cancer or Hormone Sensitive Prostate Cancer
- 37:58 – The CHAARTED Hypotheses
- 38:45 – LATITUDE Trial
- 39:19 – STAMPEDE Trial
- 39:33 – Results of Androgen Removal
- 40:17 – Castrate Resistant Metastatic Prostate Cancer or Hormone Refractory Prostate Cancer
- 40:59 – Enzalutamide
- 41:47 – Abiraterone
- 42:28 – Metastatic Bone Lesions
- 43:39 – Xofigo
- 44:10 – Phase III ALSYMPCA Study Design: Patient Eligibility
- 45:38 – Treatment of Symptomatic, Hormone Refractory Metastatic Disease with Chemotherapy
- 46:52 – Side Effects of Chemotherapy
- 48:07 – Currently Approved Therapy for Advanced Prostate Cancer
- 49:48 – Intro to Dr. Michael Liss
- 50:52 – Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
- 51:56 – Screening, PSA Testing, At – Risk Groups
- 54:35 – African American Men, Family History
- 55:18 – Individualized Risk Assessment Approach, Shared Decision Making
- 57:20 – Hereditary Prostate Cancer
- 58:43 – BRCA
- 58:54 – Genetics – Risk Using SNPs
- 59:50 – Functional vs. Non – Functional Genes
- 1:00:31 – Prostate Genetic Score
- 1:01:04 – Genomics for Treatment Decisions
- 1:04:56 – Future of Clinical Trials
- 1:06:11 – Prostate Imaging – MRI
- 1:08:29 – Software Detection Technologies, Restricted Spectrum Imaging
- 1:09:08 – PET/CT Imaging
- 1:10:32 – Oligometastatic Prostate Cancer Clinical Trials
- 1:12:35 – Q&A